doi:10.1369/jhc.5A6815.2005
Volume 54 (2): 253-262, 2006 Copyright ©The Histochemical Society, Inc. Expression and Effect of Inhibition of Aminopeptidase-A during Nephrogenesis
Department of Pathology (HBPMD, KJMA, EJS) and Department of Internal Medicine, Division of Nephrology (JFMW), Radboud University Nijmegen Medical Centre, The Netherlands Correspondence to: H.B.P.M Dijkman, Department of Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: h.dijkman{at}pathol.umcn.nl
Aminopeptidase-A (APA) is a metalloprotease that cleaves N-terminal aspartyl and glutamyl residues from peptides. Its best-known substrate is angiotensin II (Ang II), the most active compound of the reninangiotensin system (RAS). The RAS is involved in renal development. Most components of the RAS system are expressed in the developing kidney. Thus far, APA has not been studied in detail. In the present study we have evaluated the expression of APA at the protein, mRNA, and enzyme activity (EA) level in the kidney during nephrogenesis. Furthermore, we have studied the effect of inhibiting APA EA by injection of anti-APA antibodies into 1-day-old mice. APA expression was observed from the comma stage onwards, predominantly in the developing podocytes and brush borders of proximal tubular cells. Notably, APA was absent in the medulla or the renal arterioles. Inhibition of APA EA caused temporary podocyte foot-process effacement, suggesting a minimum role for APA during nephrogenesis. (J Histochem Cytochem 54:253262, 2006)
Key Words: podocyte nephrogenesis aminopeptidase-A albuminuria monoclonal antibodies inhibition enzyme activity mouse
ANGIOTENSIN II (Ang II) is the most active component of the reninangiotensin system (RAS). The RAS is involved in the regulation of vascular tone and maintenance of blood pressure. Ang II is also involved in the regulation of cell growth. In adult life, Ang II contributes to renal injury by increasing blood pressure, initiating glomerular injury, and inducing fibrosis (Ma and Fogo 2001
APA (EC 3.4.11.7) is a membrane-bound metalloprotease that cleaves N-terminal aspartyl and glutamyl residues from peptides. Its best-known substrate is Ang II (Wolf et al. 1997
Investigators have suggested that APA may be involved in blood pressure regulation and the pathogenesis of preeclampsia (Mitsui et al. 2004
Animals Female BALB/c mice in late pregnancy, aged 23 months, were purchased from Charles River Laboratories (Sulzfeld, Germany). BALB/c mouse embryos, embryonic days 1819 (E1819) postcoitum or 1-day-old mice were used to study nephrogenesis of the mouse kidney. In mice, nephrogenesis starts at E1112 (forming metanephros) and continues for 710 days postnatally (P12). In mice, 80% of the glomeruli form after birth. Microscopic examination of kidneys from E18 embryos allows studying glomeruli at various developmental stages, ranging from the earliest developmental stage (vesicle formation) in the outer cortex to mature glomeruli in the inner cortex. One-day-old mice were used to study the effect of inhibiting APA EA during nephrogenesis. All procedures involving mice were approved by the Animal Care Committee of the University of Nijmegen and conformed to the Dutch Council for Animal Care and to National Institutes of Health guidelines.
Animal Experiments
To study the effect of APA inhibition during nephrogenesis, we injected combinations of anti-APA antibodies in 1-day-old mice. Characteristics of the three rat MAbs used in this study (ASD-3, ASD-37, and ASD-41) were previously described by Mentzel et al. (1996a)
Morphological Studies
Enzyme activity of APA was visualized by enzyme histochemistry according to Lojda and Gossrau (1980)
APA mRNA was detected by RNA in situ hybridization using both a sense and an antisense 344-bp digoxigenin-labeled cRNA probe, as described previously (Mentzel et al. 1996a For LM and EM, the kidneys were immersion fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4C and washed in the same buffer. Tissue fragments were postfixed in palade-buffered 2% OsO4 for 1 hr, dehydrated, and embedded in Epon 812, Luft's procedure (Merck; Darmstadt, Germany). Semithin (1 µm) and ultrathin sections were cut on an ultratome (Reichert Ultracut S; Leica Microsystems, Vienna, Austria). The semithin slices were stained with toluidine blue and examined using LM. Ultrathin sections were stained with 4% uranyl acetate for 45 min and subsequently with lead citrate for 4 min at room temperature. Sections were examined in a JEOL 1200 EX2 electron microscope (JEOL; Tokyo, Japan). For IEM, the kidneys were immersion fixed in a mixture of 10 mM periodate, 75 mM lysine, and 2% paraformaldehyde, pH 6.2, for 3 hr. After rinsing several times in PBS, the embryonic kidneys were cryoprotected by immersion in 2.3 M sucrose, pH 7.2, for 1 hr and then frozen in liquid nitrogen. Twenty-µm-thick sections were incubated with Assman-Son-Dijkman (ASD) 3 for 18 hr at 4C. Binding of the MAb was visualized with peroxidase-labeled rabbit anti-rat IgG containing 4% normal mouse serum (Seralab/Sanbio; Uden, The Netherlands) as previously described. For IEM, ultrathin sections were cut on an ultratome (Reichert Ultracuts; Leica). Sections were examined in a JEOL 1200 EX2 electron microscope.
In mice, nephrogenesis starts at E1112 (metanephros formation) and continues for 710 days after birth. Formation of the kidney epithelium involves reciprocal inductive interactions between two mesoderm-derived structures, the uretic bud, an outgrowth of the Wolffian duct, and the adjacent metanephric mesenchyme. The bud branches into collecting ducts, and the mesenchyme differentiates into nephrons (Woolf and Loughna 1998
Histology and Immunofluorescence In the earliest histologically definable glomerular stage, the comma stage (Figure 3A ), there was only trace staining for APA by immunofluorescence (Figure 3B). Controls for background were completely negative. Its morphological shape and the presence of the earliest ingrowth of capillaries recognized by using our antibody ASD-13, which is specific for glomerular endothelium, identified the comma stage.
In the next stage, the S-stage (Figure 3C), there was staining for APA of the cells lining the vascular cleft destined to become podocytes and with lower intensity also of the epithelial cells destined to become parietal epithelial cells. In addition, cells that will develop into the proximal tubule stained faintly positive for APA without a clear polarity (Figure 3D, arrow). In the more advanced early capillary stage (Figure 3E), staining of cells destined to become podocytes is more intense (Figure 3F). Staining is membranous and strongest closer to the capillary tuft. At this stage there is luminal staining of the proximal tubules, restricted to the BB (Figure 3F, arrow). In addition, there is still weak staining of the developing parietal epithelial cells. Finally, in the mature glomerulus (Figure 3G), APA staining shows a homogeneous podocytic pattern. In addition, the BBs of the proximal tubules stain for APA (Figure 3H). In the mature kidney, faint APA expression can also be observed in the granular JG cells and on the endothelial cells of the PTC (Figure 1F), whereas no expression is observed in the efferent and afferent arterioles, the distal tubules, the loops of Henle, or the collecting ducts. To obtain more insight into the exact subcellular localization of APA during nephrogenesis, IEM on E18 embryos was carried out (Figure 4 ). In the comma stage there was only a faint APA expression (Figure 4A). In the S-stage there was strong membrane staining of both developing podocytes and parietal epithelial cells. Staining was predominantly seen on surfaces lining Bowman's space (Figure 4C). In the S-stage, proximal tubular epithelial cells showed some expression of the apical/lateral membranes (Figure 4B, arrows) and strong staining of cytoplasmic vesicles close to the luminal surface of the epithelial cells (Figure 4D). In the early capillary stage, membranes lining Bowman's capsule were still strongly positive, probably apical BB staining. In addition, early podocytes showed staining of apical, lateral, and basal membranes and sometimes carried cytoplasmic vesicles (Figure 4E). At this later stage the epithelial cells of the proximal tubules showed merely BB staining and no further staining of cytoplasmic vesicles (Figure 4F). In the mature kidney, IEM confirmed the membranous staining pattern of the podocytes (Figure 1G).
Enzyme histochemistry with a specific APA substrate on frozen sections of E18 embryonic kidneys showed that APA EA could be demonstrated in early stages (Figure 1C) and further increased in glomeruli in a more advanced developmental stage, early capillary stage (Figure 1E). In the proximal tubules, APA EA could be demonstrated in the BB (Figure 1E, arrow).
We also determined APA mRNA expression during nephrogenesis by non-radioactive RNA in situ hybridization. Glomerular APA mRNA could be demonstrated in all developmental stages. Expression is seen clearly in cells destined to become podocytes (Figure 1B, S-stage). In addition, we could demonstrate APA mRNA in developing proximal tubules (Figure 1B, inset). In the early capillary stage, expression was restricted to the podocytes (Figure 1D). In the mature kidney, APA mRNA expression was restricted to the perinuclear zone of podocytes. Expression in other compartments could not be detected or was very low (Mentzel et al. 1996a
Injection of the nephritogenic APA antibody combination ASD-37/41 in 1-day-old mice completely blocked EA (Figure 5A ) and caused albuminuria at day 1 (60,000 ± 4000 µg/ml), whereas the combination ASD-3/41 albuminuria only partially blocked EA (Figure 5B) and did not induce albuminuria (140 ± 21 µg/ml). APA EA was still absent at day 9 after injection of ASD-37/41 and was normalized at day 21 (Figure 5C). Partial foot-process effacement was present at day 1 and persisted at days 9 and 21 (Figure 5E). These abnormalities were not accompanied by albuminuria at day 9 ASD-37/41 (240 ± 47 µg/ml); ASD-3/41 (120 ± 20 µg/ml); day 21 ASD-37/41 (180 ± 25 µg/ml); ASD-3/41 (120 ± 20 µg/ml); mice were followed for 3 months after injection of antibodies. At 3 months there were no abnormalities either by LM (Figure 5D), EM (Figure 5F), or enzyme histochemistry.
From our study, it is evident that APA is expressed in the kidney during nephrogenesis. APA was detectable from the earliest stage of glomerular development, the comma stage, onwards. In later stages, APA expression was confined to the podocytes and the BB membranes of the proximal tubular epithelial cells. The subcellular localization of APA was confirmed by IEM (Mentzel et al. 1996b). We have confirmed the activity of APA by enzyme histochemistry. Of note, APA was not expressed in the medulla or in the endothelium of the renal arteries or arterioles. In the mature glomerulus only, faint expression was observed in the JG cells, the PTC, and pars media of arteries.
We were interested in APA because this enzyme is involved in the degradation of Ang II, the most active compound of the RAS system. Ang II is a cytokine that participates in renal damage and has vasoactive and profibrotic properties and contributes to kidney injury by causing hypertension and glomerulosclerosis. Impairment of Ang II degradation may influence Ang II action and, indeed, animal studies have suggested a role for APA in blood pressure regulation (Mitsui et al. 2003
Therefore, it is possible that the expression of APA in the developing kidney follows, and is dependent on, the local Ang II levels. We cannot exclude that APA is becoming more important after birth when Ang II exerts negative effects. These negative effects are shown via short-term infusion of Ang II that causes renal injury in rats, leading to the development of salt-dependent hypertension in these rats in later life (Lombardi et al. 1999 In conclusion, APA is highly expressed in the developing kidney. Complete inhibition of APA EA during nephrogenesis for 9 days after birth led only to podocyte effacement at days 9 and 21 that disappeared after 3 months, suggesting a minimum role for APA in embryonal development.
Received for publication August 16, 2005; accepted October 27, 2005
Assmann KJ, Tangelder MM, Lange WP, Tadema TM, Koene RA (1983) Membranous glomerulonephritis in the mouse. Kidney Int 24:303312[Medline] Assmann KJ, van Son JP, Dijkman HB, Koene RA (1992) A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection. J Exp Med 175:623635 Chen Y, Lasaitiene D, Friberg P (2004) The renin-angiotensin system in kidney development. Acta Physiol Scand 181:529535[CrossRef][Medline] Cheng HF, Wang JL, Vinson GP, Harris RC (1998) Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule. Am J Physiol 274:F1017 Gerlofs-Nijland ME, Assmann KJ, Dijkman HB, Dieker JW, van Son JP, Mentzel S, van Kats JP, et al. (2001) Albuminuria in mice after injection of antibodies against aminopeptidase A: role of angiotensin II. J Am Soc Nephrol 12:27112720 Guron G, Friberg P (2000) An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 18:123137[CrossRef][Medline] Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N (2004) Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 15:14751487 Ino K, Uehara C, Kikkawa F, Kajiyama H, Shibata K, Suzuki T, Khin EE, et al. (2003) Enhancement of aminopeptidase A expression during angiotensin II-induced choriocarcinoma cell proliferation through AT1 receptor involving protein kinase C- and mitogen-activated protein kinase-dependent signaling pathway. J Clin Endocrinol Metab 88:39733982 Lin Q, Taniuchi I, Kitamura D, Wang J, Kearney JF, Watanabe T, Cooper MD (1998) T and B cell development in BP-1/6C3/aminopeptidase A-deficient mice. J Immunol 160:46814687 Lojda Z, Gossrau R (1980) Study on aminopeptidase A. Histochemistry 67:267290[CrossRef][Medline] Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ (1999) Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 33:10131019 Ma L, Fogo AB (2001) Role of angiotensin II in glomerular injury. Semin Nephrol 21:544553[CrossRef][Medline] Mentzel S, Assmann KJ, Dijkman HB, De Jong AS, van Son JP, Wetzels JF, Koene RA (1996a) Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? Nephrol Dial Transplant 11:21632169 Mentzel S, Dijkman HB, van Son JP, Koene RA, Assmann KJ (1996b) Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 44:445461[Abstract] Mitsui T, Nomura S, Itakura A, Mizutani S (2004) Role of aminopeptidases in the blood pressure regulation. Biol Pharm Bull 27:768771[CrossRef][Medline] Mitsui T, Nomura S, Okada M, Ohno Y, Kobayashi H, Nakashima Y, Murata Y, et al (2003) Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mol Med 9:5762[Medline] Piscione TD, Rosenblum ND (1999) The malformed kidney: disruption of glomerular and tubular development. Clin Genet 56:341356[Medline] Wolf G, Mentzel S, Assmann KJ (1997) Aminopeptidase A: a key enzyme in the intrarenal degradation of angiotensin II. Exp Nephrol 5:364369[Medline] Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799812[CrossRef][Medline] Woolf AS, Loughna S (1998) Origin of glomerular capillaries: is the verdict in? Exp Nephrol 6:1721[CrossRef][Medline]
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||